Moreno et al. investigated the therapeutic potential of TMC435—an NS3/4a protease inhibitor—for patients infected with HCV genotypes 2–6 (TMC435 is already in phase III development for patients with HCV genotype 1 infection). 37 treatment-naive patients were enrolled; treatment consisted of 200 mg TMC435 once daily for 7 days. Antiviral activity at day 8 was greatest for genotype 6, followed by genotypes 4, 2 and 5; however, no antiviral activity was evident against genotype 3.
ORIGINAL RESEARCH PAPER
Moreno, C. et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2 to 6: TMC435-C202, a phase IIa, open-label study. J. Hepatol. doi:10.1016/j.jhep.2011.12.033
Rights and permissions
About this article
Cite this article
Proof of concept for antiviral activity of protease inhibitor TMC435 monotherapy against multiple HCV genotypes. Nat Rev Gastroenterol Hepatol 9, 186 (2012). https://doi.org/10.1038/nrgastro.2012.29
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.29
